Free Trial
NASDAQ:RVPH

Reviva Pharmaceuticals (RVPH) Stock Price, News & Analysis

Reviva Pharmaceuticals logo
$1.27 +0.06 (+4.53%)
(As of 02:35 PM ET)

About Reviva Pharmaceuticals Stock (NASDAQ:RVPH)

Key Stats

Today's Range
$1.18
$1.29
50-Day Range
$0.92
$1.50
52-Week Range
$0.60
$5.67
Volume
222,422 shs
Average Volume
384,255 shs
Market Capitalization
$42.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50
Consensus Rating
Buy

Company Overview

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

Reviva Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
53rd Percentile Overall Score

RVPH MarketRank™: 

Reviva Pharmaceuticals scored higher than 53% of companies evaluated by MarketBeat, and ranked 560th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Reviva Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Reviva Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Reviva Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Reviva Pharmaceuticals are expected to grow in the coming year, from ($0.98) to ($0.81) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Reviva Pharmaceuticals is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Reviva Pharmaceuticals is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    15.85% of the outstanding shares of Reviva Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Reviva Pharmaceuticals has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Reviva Pharmaceuticals has recently decreased by 0.19%, indicating that investor sentiment is improving.
  • Dividend Yield

    Reviva Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Reviva Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.85% of the outstanding shares of Reviva Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Reviva Pharmaceuticals has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Reviva Pharmaceuticals has recently decreased by 0.19%, indicating that investor sentiment is improving.
  • News Sentiment

    Reviva Pharmaceuticals has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Reviva Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    Only 3 people have searched for RVPH on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Reviva Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Reviva Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    27.18% of the stock of Reviva Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    63.18% of the stock of Reviva Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Reviva Pharmaceuticals' insider trading history.
Receive RVPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RVPH Stock News Headlines

RVPH: Year-End OLE Update
917 Trades… Zero Losses?
As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”
See More Headlines

RVPH Stock Analysis - Frequently Asked Questions

Reviva Pharmaceuticals' stock was trading at $5.15 at the start of the year. Since then, RVPH stock has decreased by 75.6% and is now trading at $1.2550.
View the best growth stocks for 2024 here
.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) issued its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.28) by $0.02.

Reviva Pharmaceuticals' top institutional investors include Geode Capital Management LLC (0.83%). Insiders that own company stock include Prabhu Narayan and Purav Patel.
View institutional ownership trends
.

Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Reviva Pharmaceuticals investors own include Sangamo Therapeutics (SGMO), Salesforce (CRM), Adobe (ADBE), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Airbnb (ABNB) and Marvell Technology (MRVL).

Company Calendar

Last Earnings
8/14/2024
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RVPH
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.50
High Stock Price Target
$17.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+1,120.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-39,260,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.30) per share

Miscellaneous

Free Float
24,352,000
Market Cap
$42.47 million
Optionable
Optionable
Beta
-0.05
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (NASDAQ:RVPH) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners